Cited by 975Cancer-related Molecular PathwaysChromatin Remodeling and CancerOcular Oncology and Treatments

The DOI matches its Crossref record; 221 of the 221 references it cites were found in a registry or an index; none of the 226 sources its claims cite is checked for support yet.

Cellular mechanisms of tumour suppression by the retinoblastoma gene

Open access
Burkhart, Deborah L., Sage, Julien·2008·Nature Reviews Cancer

Abstract

The retinoblastoma (RB) tumour suppressor gene is functionally inactivated in a broad range of paediatric and adult cancers, and a plethora of cellular functions and partners have been identified for the RB protein. Data from human tumours and studies from mouse models indicate that loss of RB function contributes to both cancer initiation and progression. However, we still do not know the identity of the cell types in which RB normally prevents cancer initiation in vivo, and the specific functions of RB that suppress distinct aspects of the tumorigenic process are poorly understood.

Overview

Integrity signals

Registry

Crossref · 10.1038/nrc2399

Cites

221 of 221 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Verification

Claims the paper makes

0 of 226 cited sources checked · 0 supported · 0 flagged

Show all 90 claims

  • It may state two separate claims as one. 44
  • Probably not a substantial claim. 5
48 of 48
  • The paper relies on this without support.

    Cellular senescence suppresses tumours in vivo in response to oncogenic stress.

    “Cellular senescence acts to suppress tumours in vivo in response to oncogenic stress”
  • The paper relies on this without support.

    Loss of Rb is sufficient to initiate tumorigenesis in the pituitary, thyroid and adrenal glands.

    “Furthermore, it is striking that the mechanisms of cancer initiation in the pituitary, thyroid and adrenal glands, in which loss of Rb is sufficient for tumorigenesis, are still largely unknown.”
  • The paper relies on this without support.

    p107 and p130 are rarely mutated in human cancers and resemble RB in many respects.

    “In particular, comparing the structure of RB with those of p107 and p130, which are rarely mutated in human cancers and yet are similar to RB in many ways, might help to identify mutant forms of RB that can distinguish specific cellular functions of RB.”
  • The paper relies on this without support.

    High levels of cyclin–Cdk complexes may not fully phosphorylate and inactivate RB.

    “In addition, even high levels of cyclin–Cdk complexes might be insufficient to fully phosphorylate — and functionally inactivate — RB.”
  • The paper relies on this without support.

    Tumours acquire mutations that enhance endothelial cell recruitment and new blood vessel formation to overcome hypoxia.

    “In order to over-come the growth-limiting effects of hypoxia, tumours select for mutations that increase their ability to recruit endothelial cells to form novel blood vessels in a process termed angiogenesis.”
5 of 5

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

  • Oesophageal cancer claim cites an endometrial cancer study

    Minor

    The cited reference 99 is identified in the paper as a study of endometrial carcinoma, not oesophageal cancer. The same reference is also cited for a claim about gastrointestinal cancers.

1 of 1

Citations

Cites

Flagged first, then by citations

Show all 221 references

Cited by

Sorted by citations

Items 201–300 of 975

Metadata

Authors
Burkhart, D. L., & Sage, J.
Affiliations
Stanford Medicine (US)
Corresponding author
Sage, Julien
Venue
Nature Reviews Cancer
Published
2008-07-24
Volume
8
Issue
9
Pages
671-682
ISSN
  • 1474-175X (ISSN-L)
  • 1474-1768
OpenAlex
W2071333117
Cited by
974
References
221
Citations by year
2026: 20 · 2025: 45 · 2024: 32 · 2023: 47 · 2022: 54 · 2021: 75 · 2020: 61 · 2019: 48 · 2018: 49 · 2017: 58 · 2016: 53 · 2015: 57 · 2014: 66 · 2013: 73 · 2012: 90
FWCI
4.54
Type
journal article
Language
en
Open access
Locations
  • Nature reviews. Cancer (publishedVersion)
  • PubMed (publishedVersion)
  • PubMed Central (acceptedVersion)
Funders
National Cancer Institute (R01CA114102)
Topics
  • Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Chromatin Remodeling and Cancer
  • Health Sciences › Medicine › Ophthalmology › Ocular Oncology and Treatments
Keywords
retinoblastoma gene, retinoblastoma protein, tumor suppression, tumor suppressor, tumor initiation, tumor progression, Rb inactivation, childhood cancer, mouse tumor model
MeSH terms
Animals, Cell Cycle, Cell Differentiation, Humans, Mutation, Neoplasm Invasiveness, Neoplasms, Neovascularization, Pathologic, Protein Binding, RNA Processing, Post-Transcriptional, Stem Cells, Genes, Tumor Suppressor, Genes, Retinoblastoma

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

A language model drew the claims from the paper on 2026-10-06, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-06 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review